Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

661
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
661
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

546
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of a Multicomponent Formulation: A Prospective Observational Study in Patients with Gastroesophageal Reflux Symptoms.

Pharmaceuticals (Basel, Switzerland)·2026
Same authorSame journal

Why Cardio-Rheumatology?

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Cyclooxygenase-1-Inhibition with Aspirin in Patients with Chronic Coronary Syndrome.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Diuretic dose and right atrial function interplay in patients with tricuspid regurgitation.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026
Same author

Urate-Lowering Therapy in Cardiovascular Pharmacotherapy: From Mendelian Randomization Data to Cardio-Renal-Metabolic Risk Modulation.

European heart journal. Cardiovascular pharmacotherapy·2026
Same journal

A bleeding score identifies who bleeds, not who benefits: anticoagulation decisions in postoperative atrial fibrillation after coronary surgery.

European heart journal. Cardiovascular pharmacotherapy·2026
Same journal

Statin adherence among patients with hypertension in Swedish primary health care: a QregPV cohort study using explainable machine learning.

European heart journal. Cardiovascular pharmacotherapy·2026
Same journal

Current opinion: the OCEANIC trial journey: from failure to breakthrough?

European heart journal. Cardiovascular pharmacotherapy·2026
Same journal

API-CAT Investigators' Decisions on Anticoagulation following Extended Treatment for Cancer VTE.

European heart journal. Cardiovascular pharmacotherapy·2026
Same journal

Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation.

European heart journal. Cardiovascular pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Cardiovascular pharmacotherapy in 2025.

Juan Tamargo1, Stefan Agewall2,3, Giuseppe Ambrosio4,5

  • 1Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, Avenida Ramón y Cajal s/n, Madrid 29040, Spain.

European Heart Journal. Cardiovascular Pharmacotherapy
|April 5, 2026
PubMed
Summary
This summary is machine-generated.

Cardiovascular pharmacotherapy advances in 2025 include new drug approvals and expanded uses for existing ones. Research highlights both successful trials and safety concerns, shaping future cardiovascular disease treatment strategies.

Keywords:
Cardiovascular drugsCardiovascular pharmacotherapyPharmacological strategies

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Cardiovascular diseases (CVDs) necessitate improved pharmacological treatments.
  • Current pharmacotherapy has limitations in efficacy and safety.

Purpose of the Study:

  • To review significant 2025 advances in cardiovascular pharmacotherapy.
  • To highlight new drug approvals, label expansions, and key clinical trial outcomes.

Main Methods:

  • Comprehensive review of 2025 cardiovascular drug approvals and label expansions.
  • Analysis of major randomized clinical trials for cardiovascular drugs.
  • Inclusion of data on positive, neutral, and negative trial results.
  • Documentation of drug withdrawals due to safety concerns.

Main Results:

  • Four new drugs approved: aficamten, etripamil, lerodalcibep, plozasiran.
  • Five existing drugs received expanded indications.
  • Significant clinical trials yielded both positive and negative results.
  • Andexanet-alfa withdrawn from the U.S. market due to safety issues.

Conclusions:

  • The year 2025 brought notable progress in cardiovascular pharmacotherapy.
  • New agents and expanded uses offer novel treatment avenues.
  • Ongoing research into experimental drugs promises future therapeutic options.